Inspire Medical Systems filings document formal disclosures for a medical technology company commercializing neurostimulation therapy for obstructive sleep apnea. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information, Regulation FD presentation materials, tax-related events and officer or compensation matters.
Proxy and annual-meeting filings describe director elections, stockholder voting, executive compensation, equity incentive plan authorization and governance provisions, including charter and bylaw matters. These records also disclose common stock award reserves and the governance framework for a company selling Inspire therapy through hospitals and ambulatory surgery centers.
Inspire Medical Systems, Inc. executive John Rondoni, the Chief Product and Innovation Officer, reported a tax-related share disposition. On February 9, 2026, 327 shares of common stock were withheld by the company at $66.33 per share to cover taxes on a vested restricted stock unit award. After this withholding, Rondoni directly beneficially owned 13,470 common shares.
Buchholz Richard reported disposition transactions in a Form 4 filing for INSP. The filing lists transactions totaling 327 shares at a weighted average price of $66.33 per share. Following the reported transactions, holdings were 44,567 shares.
Inspire Medical Systems' interim CFO Richard Buchholz filed an initial Form 3 reporting his beneficial ownership in Inspire Medical Systems, Inc. He directly holds 44,567 common shares, including 5,974 restricted stock units, and has employee stock options over 4,376, 5,450, 5,924 and 17,300 shares. He also reports indirect ownership of 1,475 common shares held by his son.
Inspire Medical Systems reported solid growth for 2025 while signaling a slower 2026 and governance changes. Revenue rose 14% to $911.9 million, with gross margin of 85.4% and net income of $145.4 million, or $4.89 per diluted share. Adjusted EBITDA reached $200.6 million and operating cash flow was $117.0 million, supporting $175 million of share repurchases in 2025.
Fourth quarter 2025 revenue grew 12% to $269.1 million, and net income was $136.1 million, or $4.66 per diluted share, helped by a large tax benefit from releasing a valuation allowance. For 2026, the company now guides revenue to $950 million–$1.0 billion, implying 4%–10% growth, with adjusted operating margin of 6%–8% and adjusted EPS of $1.85–$2.35, reflecting reimbursement and coding uncertainties for the Inspire V procedure.
The filing also outlines a proposal to declassify the board, moving to annual director elections after a phase-in, and bylaw amendments to remove the “for cause only” director removal provision, subject to shareholder approval at the 2026 annual meeting.
Inspire Medical Systems, Inc. received a Schedule 13G from several Wellington entities reporting a significant institutional ownership position in its common stock as of 12/31/2025.
The Wellington group entities report beneficial ownership of 2,211,091 shares of Inspire Medical common stock, representing 7.61% of the outstanding class. They report no sole voting or dispositive power, but shared voting power over 1,934,784 shares and shared dispositive power over 2,211,091 shares.
The securities are owned of record by clients of various Wellington investment advisers, which are controlled through a chain of holding companies headed by Wellington Management Group LLP. Wellington certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Inspire Medical.
Inspire Medical Systems, Inc. director Gary Lee Ellis reported receiving 304 shares of common stock on 01/15/2026 at a price of $96.47 per share. These shares were issued in lieu of cash fees under the company’s Non-Employee Director Compensation Policy, meaning his board compensation was taken in stock rather than cash.
After this award, Ellis beneficially owns 6,758 shares of Inspire Medical Systems common stock in direct ownership. The filing reflects routine director compensation rather than an open-market trade.
Inspire Medical Systems director reports stock compensation. Director Georgia Melenikiotou reported acquiring 180 shares of Inspire Medical Systems common stock on 01/15/2026 at a price of $96.47 per share. These shares were received in lieu of cash fees under the company’s Non-Employee Director Compensation Policy, meaning board fees were paid in stock instead of cash. Following this transaction, Melenikiotou beneficially owned 4,166 shares of Inspire Medical Systems common stock, held directly.
Inspire Medical Systems director Shelley G. Broader reported receiving company stock as part of her board compensation. On 01/15/2026, she acquired 200 shares of Inspire Medical Systems common stock at $96.47 per share, taken in lieu of cash fees under the company’s Non-Employee Director Compensation Policy. After this grant, she beneficially owned 4,567 common shares directly.
Inspire Medical Systems director reports stock award
Director Casey M. Tansey reported receiving 181 shares of Inspire Medical Systems common stock on January 15, 2026, coded as an acquisition. The shares were valued at $96.47 each and were received in lieu of cash fees under the company’s Non-Employee Director Compensation Policy. Following this award, Tansey holds 22,416 common shares directly.
In addition, two family trusts each hold 500 Inspire Medical Systems common shares, identified as the Kimberly Tansey Irrevocable Trust and the Kylie Tansey Irrevocable Trust, reported as indirect beneficial ownership.
Inspire Medical Systems, Inc. reported that it has issued a press release with certain preliminary, unaudited financial results for the quarter and full year ended December 31, 2025, which are still subject to closing procedures and internal control review.
The company’s board appointed Matthew J. Osberg as Chief Financial Officer, to become effective the day after Inspire files its Annual Report on Form 10-K for 2025. He will also serve as principal financial officer and principal accounting officer. His employment agreement provides a $650,000 annual base salary, a target annual cash bonus equal to 70% of base salary, a $600,000 cash sign-on bonus, and long-term equity incentives in the form of performance stock units and restricted stock units valued at $1,500,000 each on the grant date.
As part of the planned finance leadership transition, Richard J. Buchholz has been appointed interim Chief Financial Officer and designated as interim principal financial officer and interim principal accounting officer through the filing of the 2025 Form 10-K. Inspire also plans investor and analyst meetings in January 2026, supported by an investor presentation made available on its website.